MMV: The next 10 years

Chris Hentschel, President & CEO Medicines for Malaria Venture

Ahead of the curve:

“Our view is that provided we all work together, eschewing narrow interests, doctrines, and competition, we can make something remarkable happen –we can be the generation that defeats malaria. The time to set a realistic timetable to finish this job is long overdue.”MMV’s 2006 Annual Report.

Who are we ?

Multilaterals Donor Countries

Ex officio members

Malaria Endemic Countries

NGOs

PSI

SFH

Kenam

MnM FranceJapan

Netherlands

Research & Academia

Private Sector

UN Special Envoy for Malaria

FoundationsClinton Global

Initiative

From the Global Malaria Action Plan

0

1

2

3

4

5

6

2009 2012 2015 2018 2021 2024 2027 2030 2033 2036 2039 2042 2045 2048

$B

Prevention

Program

Treatment

2010 2015 2020 2025 2030 2035 2040 2045 2050

By 2030, treatment is <1% of total costs due to

lower incidence

Based on BCG analysis using information from expert interviews and other sources including: Guerra, AC et al. The Limits and Intensity of Plasmodium falciparum Transmission: Implications for Malaria Control and Elimination Worldwide. PLoS Medicine: 5 (2008). Kiszewski, A et al. “Estimated Global resources needed to attain international malaria control goals”. Bulletin of the World Health Organization 2007; 85:623-630. Korenromp, E on behalf of the RBM MERG Task Force and Malaria Morbidity. “Malaria Incidence Estimates at Country Level for the year 2004”. 2005.

But standard of care therapy is evolving:

PresumptiveMonotherapy

Presumptive CombinationTherapy

DiagnosedTherapy ?

DiagnosedTherapy Including

Asymptomatic Patients ?

??2010

… after 2010 the next chapter is becoming clearer

•Discover•Develop•Deliver

•Influence•Innovate •Integrate

Chapter 1

2000 - 2010

Chapter 2

2010 - 2020

Thank You

Ten more years….